Dystrophin and utrophin "double knockout" dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities

Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261.
Journal of Orthopaedic Research (Impact Factor: 2.99). 03/2013; 31(3). DOI: 10.1002/jor.22236
Source: PubMed


Duchenne muscular dystrophy (DMD) is a degenerative muscle disorder characterized by the lack of dystrophin expression at the sarcolemma of muscle fibers. In addition, DMD patients acquire osteopenia, fragility fractures, and scoliosis indicating that a deficiency in skeletal homeostasis coexists but little is known about the effects of DMD on bone and other connective tissues within the musculoskeletal system. Recent evidence has emerged implicating adult stem cell dysfunction in DMD myopathogenesis. Given the common mesenchymal origin of muscle and bone, we sought to investigate bone and other musculoskeletal tissues in a DMD mouse model. Here, we report that dystrophin-utrophin double knockout (dko) mice exhibit a spectrum of degenerative changes, outside skeletal muscle, in bone, articular cartilage, and intervertebral discs, in addition to reduced lifespan, muscle degeneration, spinal deformity, and cardiomyopathy previously reported. We also report these mice to have a reduced capacity for bone healing and exhibit spontaneous heterotopic ossification in the hind limb muscles. Therefore, we propose the dko mouse as a model for premature musculoskeletal aging and posit that a similar phenomenon may occur in patients with DMD. © 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aberrant activation of the nuclear factor - kappa B (NF-κB) pathway is associated with the fatal genetic muscle disease, Duchenne muscular dystrophy (DMD). NF-κB has been identified as a key player in the negative effects of chronic inflammation, which characterizes dystrophic skeletal muscle. This includes the suppression of myogenesis, which leads to decreased muscle regeneration and the exacerbation of muscular dystrophy. Several hypotheses have been proposed to explain the upregulation of NF-κB activity, and although differing significantly, they all point to the classical activation pathway, regulated by the inhibitor of kappa-B kinase (IKK). The dystrophic phenotype has been found to be significantly improved in transgenic dystrophic (mdx) mice with lowered NF-κB activity. Furthermore, several pharmacologic strategies of NF-κB blockade have demonstrated efficacy in DMD animal models, suggesting that this pathway has the potential to be a therapeutic target in human DMD patients.
    Forum on immunopathological diseases and therapeutics 01/2013; 4(2):149-160. DOI:10.1615/ForumImmunDisTher.2013008386
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heterotopic ossification (HO) and fatty infiltration (FI) often occur in diseased skeletal muscle and have been previously described in various animal models of Duchenne muscular dystrophy (DMD); however, the pathological mechanisms remain largely unknown. Dystrophin-deficient mdx mice and dystrophin/utrophin double-knockout (dKO) mice are mouse models of DMD; however, mdx mice display a strong muscle regeneration capacity, while dKO mice exhibit a much more severe phenotype, which is similar to patients with DMD. Our results revealed that more extensive HO, but not FI, occurred in the skeletal muscle of dKO mice versus mdx mice, and RhoA activation specifically occurred at the sites of HO. Moreover, the gene expression of RhoA, BMPs, and several inflammatory factors were significantly up-regulated in muscle stem cells isolated from dKO mice; while inactivation of RhoA in the cells with RhoA/ROCK inhibitor Y-27632 led to reduced osteogenic potential and improved myogenic potential. Finally, inactivation of RhoA signaling in the dKO mice with Y-27632 improved muscle regeneration and reduced the expression of BMPs, inflammation, HO, and intramyocellular lipid accumulation in both skeletal and cardiac muscle. Our results revealed that RhoA represents a major molecular switch in the regulation of HO and muscle regeneration in dystrophic skeletal muscle of mice.-Mu, X., Usas, A., Tang, Y., Lu, A., Wang, B., Weiss, K., Huard, J. RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice.
    The FASEB Journal 05/2013; DOI:10.1096/fj.13-233460 · 5.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteoarthritis, a disease characterized by cartilage degradation, abnormal subchondral bone remodelling and some grade of inflammation, and sarcopenia, a condition of pathological muscle weakness associated with altered muscle mass, strength, and function, are prevalent disorders in elderly people. There is increasing evidence that decline in lower limb muscle strength is associated with knee or hip osteoarthritis in a context of pain, altered joint stability, maladapted postures and defective neuromuscular communication. At the cellular and molecular level, chondrocytes and myoblasts share common pathological targets and pathways, and the close anatomical location of both cell types suggest a possibility of paracrine communication. In this review, we examine the relationship between osteoarthritis and sarcopenia in the musculoskeletal field, and discuss the potential advantage of concomitant therapies, or how each disorder may benefit from treatment of the other.
    Drug discovery today 08/2013; 19(3). DOI:10.1016/j.drudis.2013.08.004 · 6.69 Impact Factor
Show more